To validate the cellular effects of RBM14 overexpression in human cell lines, we selected two lung adenocarcinoma (NCI-H838; NCI-H1650) and two breast cancer (ZR-75-1; HCC70) cell lines that either exhibit high copy number and lower-than-expected mRNA/protein expression levels (“compensated”) or remain euploid at the RBM14 locus while expressing average levels of gene transcript and protein (Fig. 5d and Supplementary Fig S3a). The gene discussed is RBM14; the disease is lung adenocarcinoma.